Orthofix to Participate in Morgan Stanley Healthcare Conference
Get Alerts OFIX Hot Sheet
Join SI Premium – FREE
LEWISVILLE, Texas--(BUSINESS WIRE)-- Orthofix Medical Inc. (NASDAQ: OFIX), a leading global spine and orthopedics company, today announced that the Company will participate in the Morgan Stanley Healthcare Conference in New York City. Management is scheduled to present on Tuesday, September 13, 2023 at 1:35 p.m. ET.
Interested parties can access the live and archived webcast of the presentation on the Investors section of the Orthofix website at ir.orthofix.com.
About Orthofix:
On January 5, 2023, Orthofix and SeaSpine merged to form a leading global spine and orthopedics company with a comprehensive portfolio of biologics, innovative spinal hardware, bone growth therapies, specialized orthopedic solutions, and a leading surgical navigation system. Its products are distributed in approximately 68 countries worldwide.
The Company is headquartered in Lewisville, Texas and has primary offices in Carlsbad, CA, with a focus on spine and biologics product innovation and surgeon education, and Verona, Italy, with an emphasis on product innovation, production, and medical education for orthopedics. The combined Company’s global R&D, commercial and manufacturing footprint also includes facilities and offices in Irvine, CA, Toronto, Canada, Sunnyvale, CA, Wayne, PA, Olive Branch, MS, Maidenhead, UK, Munich, Germany, Paris, France and Sao Paulo, Brazil. A new name for the combined entity will be announced at a future date; the Company will continue to operate as Orthofix until said announcement.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230831851521/en/
Louisa Smith, Gilmartin Group
[email protected]
Source: Orthofix Medical Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Energy Impact Partners Deepens Partnership with Singapore Economic Development Board to Advance Energy Innovation & Decarbonisation
- Endometriosis Pain Pipeline Insights 2026: Novel Mechanisms, Promising Candidates, and Competitive Landscape by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie
- Ovarian Cancer Pipeline 2026: Emerging Drugs, Regulatory Milestones, and Strategic Moves by Leading Players | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer Ingelheim, Impact
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share